Physician profile
Hertzel K Sure
NPI 1083727762
$90,713.77
in general payments reported to CMS, 2019-2025
67 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,797 · 2020: $2,845 · 2021: $3,307 · 2022: $16K · 2023: $23K · 2024: $23K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,254.00 |
| Food and Beverage | $10,529.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $71,552.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,664.53 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,243.09 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Abbvie INC. | $1,981.95 | 2020-2025 | Qulipta, Vraylar, Linzess |
| Novo Nordisk INC | $1,493.67 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $1,153.37 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,001.59 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $955.11 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $907.17 | 2020-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $571.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Cognoa, INC. | $569.78 | 2022 | |
| Pfizer INC. | $480.85 | 2020-2025 | |
| Allergan, INC. | $450.14 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $400.89 | 2019-2023 | |
| Genzyme Corporation | $382.55 | 2021-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hertzel Sure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.